Exact Mass: 724.5125
Exact Mass Matches: 724.5125
Found 257 metabolites which its exact mass value is equals to given mass value 724.5125,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
PA(16:0/22:4(7Z,10Z,13Z,16Z))
PA(16:0/22:4(7Z,10Z,13Z,16Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(16:0/22:4(7Z,10Z,13Z,16Z)), in particular, consists of one chain of palmitic acid at the C-1 position and one chain of adrenic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.
PA(18:0/20:4(5Z,8Z,11Z,14Z))
PA(18:0/20:4(5Z,8Z,11Z,14Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(18:0/20:4(5Z,8Z,11Z,14Z)), in particular, consists of one chain of stearic acid at the C-1 position and one chain of arachidonic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.
PA(18:0/20:4(8Z,11Z,14Z,17Z))
PA(18:0/20:4(8Z,11Z,14Z,17Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(18:0/20:4(8Z,11Z,14Z,17Z)), in particular, consists of one chain of stearic acid at the C-1 position and one chain of eicosatetraenoic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.
PA(18:1(11Z)/20:3(5Z,8Z,11Z))
PA(18:1(11Z)/20:3(5Z,8Z,11Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(18:1(11Z)/20:3(5Z,8Z,11Z)), in particular, consists of one chain of cis-vaccenic acid at the C-1 position and one chain of mead acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.
PA(18:1(9Z)/20:3(5Z,8Z,11Z))
PA(18:1(9Z)/20:3(5Z,8Z,11Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(18:1(9Z)/20:3(5Z,8Z,11Z)), in particular, consists of one chain of oleic acid at the C-1 position and one chain of mead acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.
PA(18:3(6Z,9Z,12Z)/20:1(11Z))
PA(18:3(6Z,9Z,12Z)/20:1(11Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(18:3(6Z,9Z,12Z)/20:1(11Z)), in particular, consists of one chain of gamma-linolenic acid at the C-1 position and one chain of eicosenoic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.
PA(18:3(9Z,12Z,15Z)/20:1(11Z))
PA(18:3(9Z,12Z,15Z)/20:1(11Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(18:3(9Z,12Z,15Z)/20:1(11Z)), in particular, consists of one chain of alpha-linolenic acid at the C-1 position and one chain of eicosenoic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.
PA(18:4(6Z,9Z,12Z,15Z)/20:0)
PA(18:4(6Z,9Z,12Z,15Z)/20:0) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(18:4(6Z,9Z,12Z,15Z)/20:0), in particular, consists of one chain of stearidonic acid at the C-1 position and one chain of arachidic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.
PA(20:0/18:4(6Z,9Z,12Z,15Z))
PA(20:0/18:4(6Z,9Z,12Z,15Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(20:0/18:4(6Z,9Z,12Z,15Z)), in particular, consists of one chain of arachidic acid at the C-1 position and one chain of stearidonic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.
PA(20:1(11Z)/18:3(6Z,9Z,12Z))
PA(20:1(11Z)/18:3(6Z,9Z,12Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(20:1(11Z)/18:3(6Z,9Z,12Z)), in particular, consists of one chain of eicosenoic acid at the C-1 position and one chain of gamma-linolenic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.
PA(20:1(11Z)/18:3(9Z,12Z,15Z))
PA(20:1(11Z)/18:3(9Z,12Z,15Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(20:1(11Z)/18:3(9Z,12Z,15Z)), in particular, consists of one chain of eicosenoic acid at the C-1 position and one chain of alpha-linolenic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.
PA(20:3(5Z,8Z,11Z)/18:1(11Z))
PA(20:3(5Z,8Z,11Z)/18:1(11Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(20:3(5Z,8Z,11Z)/18:1(11Z)), in particular, consists of one chain of mead acid at the C-1 position and one chain of cis-vaccenic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.
PA(20:3(5Z,8Z,11Z)/18:1(9Z))
PA(20:3(5Z,8Z,11Z)/18:1(9Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(20:3(5Z,8Z,11Z)/18:1(9Z)), in particular, consists of one chain of mead acid at the C-1 position and one chain of oleic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.
PA(20:4(5Z,8Z,11Z,14Z)/18:0)
PA(20:4(5Z,8Z,11Z,14Z)/18:0) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(20:4(5Z,8Z,11Z,14Z)/18:0), in particular, consists of one chain of arachidonic acid at the C-1 position and one chain of stearic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.
PA(20:4(8Z,11Z,14Z,17Z)/18:0)
PA(20:4(8Z,11Z,14Z,17Z)/18:0) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(20:4(8Z,11Z,14Z,17Z)/18:0), in particular, consists of one chain of eicosatetraenoic acid at the C-1 position and one chain of stearic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.
PA(22:4(7Z,10Z,13Z,16Z)/16:0)
PA(22:4(7Z,10Z,13Z,16Z)/16:0) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(22:4(7Z,10Z,13Z,16Z)/16:0), in particular, consists of one chain of adrenic acid at the C-1 position and one chain of palmitic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.
PA(20:2(11Z,14Z)/18:2(9Z,12Z))
PA(20:2(11Z,14Z)/18:2(9Z,12Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(20:2(11Z,14Z)/18:2(9Z,12Z)), in particular, consists of one chain of eicosadienoic acid at the C-1 position and one chain of linoleic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.
PA(18:1(11Z)/20:3(8Z,11Z,14Z))
PA(18:1(11Z)/20:3(8Z,11Z,14Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(18:1(11Z)/20:3(8Z,11Z,14Z)), in particular, consists of one chain of cis-vaccenic acid at the C-1 position and one chain of dihomo-gamma-linolenic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.
PA(18:1(9Z)/20:3(8Z,11Z,14Z))
PA(18:1(9Z)/20:3(8Z,11Z,14Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(18:1(9Z)/20:3(8Z,11Z,14Z)), in particular, consists of one chain of oleic acid at the C-1 position and one chain of dihomo-gamma-linolenic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.
PA(18:2(9Z,12Z)/20:2(11Z,14Z))
PA(18:2(9Z,12Z)/20:2(11Z,14Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(18:2(9Z,12Z)/20:2(11Z,14Z)), in particular, consists of one chain of linoleic acid at the C-1 position and one chain of eicosadienoic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.
PA(20:3(8Z,11Z,14Z)/18:1(11Z))
PA(20:3(8Z,11Z,14Z)/18:1(11Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(20:3(8Z,11Z,14Z)/18:1(11Z)), in particular, consists of one chain of dihomo-gamma-linolenic acid at the C-1 position and one chain of cis-vaccenic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.
PA(20:3(8Z,11Z,14Z)/18:1(9Z))
PA(20:3(8Z,11Z,14Z)/18:1(9Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(20:3(8Z,11Z,14Z)/18:1(9Z)), in particular, consists of one chain of dihomo-gamma-linolenic acid at the C-1 position and one chain of oleic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.
SM(d17:2(4E,8Z)/18:2(10E,12Z)+=O(9))
SM(d17:2(4E,8Z)/18:2(10E,12Z)+=O(9)) is a type of oxidized sphingolipid found in animal cell membranes. It usually consists of phosphorylcholine and ceramide. SM(d17:2(4E,8Z)/18:2(10E,12Z)+=O(9)) consists of a sphingosine backbone and a 9-oxo-octadecadienoyl chain. In humans, sphingomyelin is the only membrane phospholipid not derived from glycerol. Like all sphingolipids, SM has a ceramide core (sphingosine bonded to a fatty acid via an amide linkage). In addition, it contains one polar head group, which is either phosphocholine or phosphoethanolamine. The plasma membrane of cells is highly enriched in sphingomyelin and is considered largely to be found in the exoplasmic leaflet of the cell membrane. However, there is some evidence that there may also be a sphingomyelin pool in the inner leaflet of the membrane. Moreover, neutral sphingomyelinase-2, an enzyme that breaks down sphingomyelin into ceramide, has been found to localize exclusively to the inner leaflet further suggesting that there may be sphingomyelin present there. Sphingomyelin can accumulate in a rare hereditary disease called Niemann-Pick Disease, types A and B. Niemann-Pick disease is a genetically-inherited disease caused by a deficiency in the enzyme sphingomyelinase, which causes the accumulation of sphingomyelin in spleen, liver, lungs, bone marrow, and the brain, causing irreversible neurological damage. SMs play a role in signal transduction. Sphingomyelins are synthesized by the transfer of phosphorylcholine from phosphatidylcholine to a ceramide in a reaction catalyzed by sphingomyelin synthase.
SM(d17:2(4E,8Z)/18:2(9Z,11E)+=O(13))
SM(d17:2(4E,8Z)/18:2(9Z,11E)+=O(13)) is a type of oxidized sphingolipid found in animal cell membranes. It usually consists of phosphorylcholine and ceramide. SM(d17:2(4E,8Z)/18:2(9Z,11E)+=O(13)) consists of a sphingosine backbone and a 13-oxo-octadecadienoyl chain. In humans, sphingomyelin is the only membrane phospholipid not derived from glycerol. Like all sphingolipids, SM has a ceramide core (sphingosine bonded to a fatty acid via an amide linkage). In addition, it contains one polar head group, which is either phosphocholine or phosphoethanolamine. The plasma membrane of cells is highly enriched in sphingomyelin and is considered largely to be found in the exoplasmic leaflet of the cell membrane. However, there is some evidence that there may also be a sphingomyelin pool in the inner leaflet of the membrane. Moreover, neutral sphingomyelinase-2, an enzyme that breaks down sphingomyelin into ceramide, has been found to localize exclusively to the inner leaflet further suggesting that there may be sphingomyelin present there. Sphingomyelin can accumulate in a rare hereditary disease called Niemann-Pick Disease, types A and B. Niemann-Pick disease is a genetically-inherited disease caused by a deficiency in the enzyme sphingomyelinase, which causes the accumulation of sphingomyelin in spleen, liver, lungs, bone marrow, and the brain, causing irreversible neurological damage. SMs play a role in signal transduction. Sphingomyelins are synthesized by the transfer of phosphorylcholine from phosphatidylcholine to a ceramide in a reaction catalyzed by sphingomyelin synthase.
SM(d17:2(4E,8Z)/18:3(10,12,15)-OH(9))
SM(d17:2(4E,8Z)/18:3(10,12,15)-OH(9)) is a type of oxidized sphingolipid found in animal cell membranes. It usually consists of phosphorylcholine and ceramide. SM(d17:2(4E,8Z)/18:3(10,12,15)-OH(9)) consists of a sphingosine backbone and a 9-hydroxyoctadecatrienoyl chain. In humans, sphingomyelin is the only membrane phospholipid not derived from glycerol. Like all sphingolipids, SM has a ceramide core (sphingosine bonded to a fatty acid via an amide linkage). In addition, it contains one polar head group, which is either phosphocholine or phosphoethanolamine. The plasma membrane of cells is highly enriched in sphingomyelin and is considered largely to be found in the exoplasmic leaflet of the cell membrane. However, there is some evidence that there may also be a sphingomyelin pool in the inner leaflet of the membrane. Moreover, neutral sphingomyelinase-2, an enzyme that breaks down sphingomyelin into ceramide, has been found to localize exclusively to the inner leaflet further suggesting that there may be sphingomyelin present there. Sphingomyelin can accumulate in a rare hereditary disease called Niemann-Pick Disease, types A and B. Niemann-Pick disease is a genetically-inherited disease caused by a deficiency in the enzyme sphingomyelinase, which causes the accumulation of sphingomyelin in spleen, liver, lungs, bone marrow, and the brain, causing irreversible neurological damage. SMs play a role in signal transduction. Sphingomyelins are synthesized by the transfer of phosphorylcholine from phosphatidylcholine to a ceramide in a reaction catalyzed by sphingomyelin synthase.
SM(d17:2(4E,8Z)/18:3(9,11,15)-OH(13))
SM(d17:2(4E,8Z)/18:3(9,11,15)-OH(13)) is a type of oxidized sphingolipid found in animal cell membranes. It usually consists of phosphorylcholine and ceramide. SM(d17:2(4E,8Z)/18:3(9,11,15)-OH(13)) consists of a sphingosine backbone and a 13-hydroxyoctadecatrienoyl chain. In humans, sphingomyelin is the only membrane phospholipid not derived from glycerol. Like all sphingolipids, SM has a ceramide core (sphingosine bonded to a fatty acid via an amide linkage). In addition, it contains one polar head group, which is either phosphocholine or phosphoethanolamine. The plasma membrane of cells is highly enriched in sphingomyelin and is considered largely to be found in the exoplasmic leaflet of the cell membrane. However, there is some evidence that there may also be a sphingomyelin pool in the inner leaflet of the membrane. Moreover, neutral sphingomyelinase-2, an enzyme that breaks down sphingomyelin into ceramide, has been found to localize exclusively to the inner leaflet further suggesting that there may be sphingomyelin present there. Sphingomyelin can accumulate in a rare hereditary disease called Niemann-Pick Disease, types A and B. Niemann-Pick disease is a genetically-inherited disease caused by a deficiency in the enzyme sphingomyelinase, which causes the accumulation of sphingomyelin in spleen, liver, lungs, bone marrow, and the brain, causing irreversible neurological damage. SMs play a role in signal transduction. Sphingomyelins are synthesized by the transfer of phosphorylcholine from phosphatidylcholine to a ceramide in a reaction catalyzed by sphingomyelin synthase.
(2S)-2-O-(tetradecanoyl)-3-O-(9Z,12Z,15Z-octadecatrienoyl)-glyceryl-beta-D-galactopyranoside
PA(18:0/20:4)
PA(18:2(9Z,12Z)/20:2(11Z,14Z))
PA(18:3(9Z,12Z,15Z)/20:1(11Z))
PA(20:1(11Z)/18:3(9Z,12Z,15Z))
PA(20:2(11Z,14Z)/18:2(9Z,12Z))
PA(22:4(7Z,10Z,13Z,16Z)/16:0)
PA(16:0/22:4(7Z,10Z,13Z,16Z))
Siphonaxanthin octenoate
1-Stearoyl-2-arachidonoylphosphatidic acid
A phosphatidic acid in which the acyl groups at positions 1 and 2 are specifed as stearoyl and arachidonoyl respectively.
[(8E,12E,16E)-2-[[(9Z,12Z)-heptadeca-9,12-dienoyl]amino]-3,4-dihydroxyoctadeca-8,12,16-trienyl] 2-(trimethylazaniumyl)ethyl phosphate
[1-decanoyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (10Z,13Z,16Z)-docosa-10,13,16-trienoate
[2-[(9Z,12Z)-hexadeca-9,12-dienoyl]oxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropyl] (Z)-hexadec-9-enoate
[1-[(Z)-tetradec-9-enoyl]oxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (9Z,12Z)-octadeca-9,12-dienoate
[1-[(Z)-pentadec-9-enoyl]oxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (9Z,12Z)-heptadeca-9,12-dienoate
[1-tetradecanoyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (9Z,12Z,15Z)-octadeca-9,12,15-trienoate
[2-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]oxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropyl] hexadecanoate
[1-[(Z)-tridec-9-enoyl]oxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (9Z,12Z)-nonadeca-9,12-dienoate
[1-dodecanoyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (11Z,14Z,17Z)-icosa-11,14,17-trienoate
[1-[(Z)-octadec-9-enoyl]oxy-3-phosphonooxypropan-2-yl] (11Z,14Z,17Z)-icosa-11,14,17-trienoate
[1-[(9Z,12Z)-heptadeca-9,12-dienoyl]oxy-3-phosphonooxypropan-2-yl] (11Z,14Z)-henicosa-11,14-dienoate
[2-[(9Z,12Z)-nonadeca-9,12-dienoyl]oxy-3-phosphonooxypropyl] (9Z,12Z)-nonadeca-9,12-dienoate
(1-hexadecanoyloxy-3-phosphonooxypropan-2-yl) (10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoate
(1-phosphonooxy-3-tetradecanoyloxypropan-2-yl) (12Z,15Z,18Z,21Z)-tetracosa-12,15,18,21-tetraenoate
[2-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxy-3-phosphonooxypropyl] docosanoate
[2-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoyl]oxy-3-phosphonooxypropyl] (Z)-icos-11-enoate
(1-dodecanoyloxy-3-phosphonooxypropan-2-yl) (14Z,17Z,20Z,23Z)-hexacosa-14,17,20,23-tetraenoate
[1-[(Z)-hexadec-9-enoyl]oxy-3-phosphonooxypropan-2-yl] (10Z,13Z,16Z)-docosa-10,13,16-trienoate
(1-octadecanoyloxy-3-phosphonooxypropan-2-yl) (8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoate
[2-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoyl]oxy-3-phosphonooxypropyl] icosanoate
[1-[(9Z,12Z)-hexadeca-9,12-dienoyl]oxy-3-phosphonooxypropan-2-yl] (13Z,16Z)-docosa-13,16-dienoate
[2-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]oxy-3-phosphonooxypropyl] (Z)-docos-13-enoate
[1-[(9Z,12Z)-octadeca-9,12-dienoyl]oxy-3-phosphonooxypropan-2-yl] (11Z,14Z)-icosa-11,14-dienoate
[(2R)-1-octadecanoyloxy-3-phosphonooxypropan-2-yl] (5E,8E,11E,14E)-icosa-5,8,11,14-tetraenoate
[(2R)-1-[(E)-octadec-6-enoyl]oxy-3-phosphonooxypropan-2-yl] (5E,8E,11E)-icosa-5,8,11-trienoate
[(2R)-2-[(E)-tetradec-9-enoyl]oxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropyl] (9E,12E)-octadeca-9,12-dienoate
[2-[(9E,11E,13E)-hexadeca-9,11,13-trienoyl]oxy-3-phosphonooxypropyl] (E)-docos-11-enoate
[(2S)-1-[(E)-tetradec-9-enoyl]oxy-3-[(2R,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (2E,4E)-octadeca-2,4-dienoate
[(2R)-1-[(9E,12E,15E)-octadeca-9,12,15-trienoyl]oxy-3-phosphonooxypropan-2-yl] (E)-icos-13-enoate
[(2R)-1-[(6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoyl]oxy-3-phosphonooxypropan-2-yl] icosanoate
[1-carboxy-3-[2-[(9E,11E,13E)-hexadeca-9,11,13-trienoyl]oxy-3-[(7E,9E,11E,13E,15E)-octadeca-7,9,11,13,15-pentaenoyl]oxypropoxy]propyl]-trimethylazanium
[(2R)-2-dodecanoyloxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropyl] (5E,8E,11E)-icosa-5,8,11-trienoate
[1-carboxy-3-[3-[(7E,9E,11E,13E,15E,17E,19E)-docosa-7,9,11,13,15,17,19-heptaenoyl]oxy-2-[(E)-dodec-5-enoyl]oxypropoxy]propyl]-trimethylazanium
[(2S)-1-dodecanoyloxy-3-[(2R,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (5E,8E,11E)-icosa-5,8,11-trienoate
[(2R)-1-[(E)-octadec-13-enoyl]oxy-3-phosphonooxypropan-2-yl] (5E,8E,11E)-icosa-5,8,11-trienoate
[(2R)-2-[(9E,12E,15E)-octadeca-9,12,15-trienoyl]oxy-3-phosphonooxypropyl] (E)-icos-13-enoate
[(2R)-2-[(E)-octadec-9-enoyl]oxy-3-phosphonooxypropyl] (5E,8E,11E)-icosa-5,8,11-trienoate
[(2R)-1-[(9E,11E)-octadeca-9,11-dienoyl]oxy-3-phosphonooxypropan-2-yl] (11E,14E)-icosa-11,14-dienoate
[(2R)-1-[(9E,12E)-octadeca-9,12-dienoyl]oxy-3-phosphonooxypropan-2-yl] (5E,8E)-icosa-5,8-dienoate
[1-carboxy-3-[3-[(4E,7E)-deca-4,7-dienoyl]oxy-2-[(6E,9E,12E,15E,18E,21E)-tetracosa-6,9,12,15,18,21-hexaenoyl]oxypropoxy]propyl]-trimethylazanium
[(2R)-2-[(6E,9E,12E)-octadeca-6,9,12-trienoyl]oxy-3-phosphonooxypropyl] (E)-icos-11-enoate
[(2R)-2-[(2E,4E)-octadeca-2,4-dienoyl]oxy-3-phosphonooxypropyl] (5E,8E)-icosa-5,8-dienoate
[(2R)-2-[(E)-octadec-13-enoyl]oxy-3-phosphonooxypropyl] (5E,8E,11E)-icosa-5,8,11-trienoate
[(2R)-2-[(E)-tetradec-9-enoyl]oxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropyl] (9E,11E)-octadeca-9,11-dienoate
[(2R)-1-octadec-17-enoyloxy-3-phosphonooxypropan-2-yl] (8E,11E,14E)-icosa-8,11,14-trienoate
[1-carboxy-3-[3-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-2-[(11E,13E,15E)-octadeca-11,13,15-trienoyl]oxypropoxy]propyl]-trimethylazanium
[2-[(9E,11E,13E)-hexadeca-9,11,13-trienoyl]oxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropyl] hexadecanoate
[(2R)-1-[(E)-octadec-13-enoyl]oxy-3-phosphonooxypropan-2-yl] (8E,11E,14E)-icosa-8,11,14-trienoate
[1-carboxy-3-[2-[(7E,9E,11E,13E,15E,17E,19E)-docosa-7,9,11,13,15,17,19-heptaenoyl]oxy-3-[(E)-dodec-5-enoyl]oxypropoxy]propyl]-trimethylazanium
[1-carboxy-3-[2-[(4E,7E,10E,13E,16E,19E)-docosa-4,7,10,13,16,19-hexaenoyl]oxy-3-[(6E,9E)-dodeca-6,9-dienoyl]oxypropoxy]propyl]-trimethylazanium
[1-carboxy-3-[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-[(11E,13E,15E)-octadeca-11,13,15-trienoyl]oxypropoxy]propyl]-trimethylazanium
[1-carboxy-3-[2-[(4E,7E,10E,13E,16E)-nonadeca-4,7,10,13,16-pentaenoyl]oxy-3-[(6E,9E,12E)-pentadeca-6,9,12-trienoyl]oxypropoxy]propyl]-trimethylazanium
[(2R)-1-octadecanoyloxy-3-phosphonooxypropan-2-yl] (7E,10E,13E,16E)-icosa-7,10,13,16-tetraenoate
[(2R)-2-tetradecanoyloxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropyl] (6E,9E,12E)-octadeca-6,9,12-trienoate
[(2R)-2-[(E)-octadec-4-enoyl]oxy-3-phosphonooxypropyl] (8E,11E,14E)-icosa-8,11,14-trienoate
[(2R)-1-[(6E,9E,12E)-octadeca-6,9,12-trienoyl]oxy-3-phosphonooxypropan-2-yl] (E)-icos-11-enoate
[(2R)-2-[(6E,9E,12E)-octadeca-6,9,12-trienoyl]oxy-3-phosphonooxypropyl] (E)-icos-13-enoate
[2-[(4E,7E)-hexadeca-4,7-dienoyl]oxy-3-phosphonooxypropyl] (14E,16E)-docosa-14,16-dienoate
[(2R)-2-dodecanoyloxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropyl] (8E,11E,14E)-icosa-8,11,14-trienoate
[1-carboxy-3-[2-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxy-3-[(9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoyl]oxypropoxy]propyl]-trimethylazanium
[(2S)-1-tetradecanoyloxy-3-[(2R,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (6E,9E,12E)-octadeca-6,9,12-trienoate
[(2R)-2-[(E)-octadec-9-enoyl]oxy-3-phosphonooxypropyl] (8E,11E,14E)-icosa-8,11,14-trienoate
[1-carboxy-3-[3-[(4E,7E,10E,13E,16E,19E)-docosa-4,7,10,13,16,19-hexaenoyl]oxy-2-[(6E,9E)-dodeca-6,9-dienoyl]oxypropoxy]propyl]-trimethylazanium
[(2R)-1-[(E)-octadec-9-enoyl]oxy-3-phosphonooxypropan-2-yl] (8E,11E,14E)-icosa-8,11,14-trienoate
[(2R)-2-octadecanoyloxy-3-phosphonooxypropyl] (5E,8E,11E,14E)-icosa-5,8,11,14-tetraenoate
[(2R)-1-[(9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoyl]oxy-3-phosphonooxypropan-2-yl] icosanoate
[(2R)-1-[(6E,9E)-octadeca-6,9-dienoyl]oxy-3-phosphonooxypropan-2-yl] (5E,8E)-icosa-5,8-dienoate
[(2R)-2-[(E)-tetradec-9-enoyl]oxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropyl] (2E,4E)-octadeca-2,4-dienoate
[(2R)-1-[(9E,11E)-octadeca-9,11-dienoyl]oxy-3-phosphonooxypropan-2-yl] (5E,8E)-icosa-5,8-dienoate
[(2R)-2-tetradecanoyloxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropyl] (9E,12E,15E)-octadeca-9,12,15-trienoate
[(2R)-1-[(E)-octadec-7-enoyl]oxy-3-phosphonooxypropan-2-yl] (8E,11E,14E)-icosa-8,11,14-trienoate
[(2R)-2-[(E)-octadec-7-enoyl]oxy-3-phosphonooxypropyl] (8E,11E,14E)-icosa-8,11,14-trienoate
[(2R)-3-phosphonooxy-2-tetradecanoyloxypropyl] (5E,8E,11E,14E)-tetracosa-5,8,11,14-tetraenoate
[1-carboxy-3-[2-[(4E,7E)-deca-4,7-dienoyl]oxy-3-[(6E,9E,12E,15E,18E,21E)-tetracosa-6,9,12,15,18,21-hexaenoyl]oxypropoxy]propyl]-trimethylazanium
[(2R)-2-[(9E,12E)-octadeca-9,12-dienoyl]oxy-3-phosphonooxypropyl] (11E,14E)-icosa-11,14-dienoate
[(2R)-2-[(E)-octadec-7-enoyl]oxy-3-phosphonooxypropyl] (5E,8E,11E)-icosa-5,8,11-trienoate
[(2R)-2-[(E)-octadec-6-enoyl]oxy-3-phosphonooxypropyl] (5E,8E,11E)-icosa-5,8,11-trienoate
[(2R)-2-hexadecanoyloxy-3-phosphonooxypropyl] (7E,10E,13E,16E)-docosa-7,10,13,16-tetraenoate
[(2R)-2-[(9E,12E)-octadeca-9,12-dienoyl]oxy-3-phosphonooxypropyl] (5E,8E)-icosa-5,8-dienoate
[(2R)-2-octadec-17-enoyloxy-3-phosphonooxypropyl] (8E,11E,14E)-icosa-8,11,14-trienoate
[(2S)-1-[(E)-tetradec-9-enoyl]oxy-3-[(2R,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (9E,12E)-octadeca-9,12-dienoate
[(2R)-1-[(E)-octadec-4-enoyl]oxy-3-phosphonooxypropan-2-yl] (8E,11E,14E)-icosa-8,11,14-trienoate
[(2R)-1-octadec-17-enoyloxy-3-phosphonooxypropan-2-yl] (5E,8E,11E)-icosa-5,8,11-trienoate
[(2R)-2-[(9E,12E,15E)-octadeca-9,12,15-trienoyl]oxy-3-phosphonooxypropyl] (E)-icos-11-enoate
[(2R)-1-[(2E,4E)-octadeca-2,4-dienoyl]oxy-3-phosphonooxypropan-2-yl] (5E,8E)-icosa-5,8-dienoate
[(2S)-1-[(E)-pentadec-9-enoyl]oxy-3-[(2R,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (9E,12E)-heptadeca-9,12-dienoate
[(2R)-2-octadec-17-enoyloxy-3-phosphonooxypropyl] (5E,8E,11E)-icosa-5,8,11-trienoate
[2-[(4E,7E)-hexadeca-4,7-dienoyl]oxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropyl] (E)-hexadec-7-enoate
[(2R)-1-[(E)-octadec-6-enoyl]oxy-3-phosphonooxypropan-2-yl] (8E,11E,14E)-icosa-8,11,14-trienoate
[(2R)-1-[(E)-octadec-11-enoyl]oxy-3-phosphonooxypropan-2-yl] (8E,11E,14E)-icosa-8,11,14-trienoate
[(2R)-1-[(9E,12E,15E)-octadeca-9,12,15-trienoyl]oxy-3-phosphonooxypropan-2-yl] (E)-icos-11-enoate
[(2R)-1-[(2E,4E)-octadeca-2,4-dienoyl]oxy-3-phosphonooxypropan-2-yl] (11E,14E)-icosa-11,14-dienoate
[(2S)-1-dodecanoyloxy-3-[(2R,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (8E,11E,14E)-icosa-8,11,14-trienoate
[(2S)-1-[(E)-tetradec-9-enoyl]oxy-3-[(2R,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (9E,11E)-octadeca-9,11-dienoate
[(2S)-1-tetradecanoyloxy-3-[(2R,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (9E,12E,15E)-octadeca-9,12,15-trienoate
[1-carboxy-3-[3-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxy-2-[(9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoyl]oxypropoxy]propyl]-trimethylazanium
[1-carboxy-3-[2-[(7E,9E,11E,13E,15E,17E)-icosa-7,9,11,13,15,17-hexaenoyl]oxy-3-[(7E,9E)-tetradeca-7,9-dienoyl]oxypropoxy]propyl]-trimethylazanium
[(2R)-2-[(9E,11E)-octadeca-9,11-dienoyl]oxy-3-phosphonooxypropyl] (11E,14E)-icosa-11,14-dienoate
[(2R)-2-octadecanoyloxy-3-phosphonooxypropyl] (7E,10E,13E,16E)-icosa-7,10,13,16-tetraenoate
[(2R)-2-[(6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoyl]oxy-3-phosphonooxypropyl] icosanoate
[(2R)-2-[(E)-octadec-6-enoyl]oxy-3-phosphonooxypropyl] (8E,11E,14E)-icosa-8,11,14-trienoate
[(2R)-2-[(9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoyl]oxy-3-phosphonooxypropyl] icosanoate
[(2R)-1-hexadecanoyloxy-3-phosphonooxypropan-2-yl] (7E,10E,13E,16E)-docosa-7,10,13,16-tetraenoate
[(2R)-2-[(2E,4E)-octadeca-2,4-dienoyl]oxy-3-phosphonooxypropyl] (11E,14E)-icosa-11,14-dienoate
[(2R)-1-[(E)-octadec-11-enoyl]oxy-3-phosphonooxypropan-2-yl] (5E,8E,11E)-icosa-5,8,11-trienoate
[(2R)-2-[(9E,11E)-octadeca-9,11-dienoyl]oxy-3-phosphonooxypropyl] (5E,8E)-icosa-5,8-dienoate
[(2R)-1-[(E)-octadec-4-enoyl]oxy-3-phosphonooxypropan-2-yl] (5E,8E,11E)-icosa-5,8,11-trienoate
[2-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxy-3-phosphonooxypropyl] docosanoate
[(2R)-1-[(6E,9E,12E)-octadeca-6,9,12-trienoyl]oxy-3-phosphonooxypropan-2-yl] (E)-icos-13-enoate
[(2R)-2-[(E)-octadec-11-enoyl]oxy-3-phosphonooxypropyl] (5E,8E,11E)-icosa-5,8,11-trienoate
[1-carboxy-3-[2-[(7E,10E,13E,16E,19E)-docosa-7,10,13,16,19-pentaenoyl]oxy-3-[(3E,6E,9E)-dodeca-3,6,9-trienoyl]oxypropoxy]propyl]-trimethylazanium
[(2R)-1-[(E)-octadec-9-enoyl]oxy-3-phosphonooxypropan-2-yl] (5E,8E,11E)-icosa-5,8,11-trienoate
[(2R)-2-[(E)-octadec-11-enoyl]oxy-3-phosphonooxypropyl] (8E,11E,14E)-icosa-8,11,14-trienoate
[1-carboxy-3-[2-[(5E,8E,11E,14E,17E)-icosa-5,8,11,14,17-pentaenoyl]oxy-3-[(5E,8E,11E)-tetradeca-5,8,11-trienoyl]oxypropoxy]propyl]-trimethylazanium
[1-carboxy-3-[3-[(7E,10E,13E,16E,19E)-docosa-7,10,13,16,19-pentaenoyl]oxy-2-[(3E,6E,9E)-dodeca-3,6,9-trienoyl]oxypropoxy]propyl]-trimethylazanium
[1-carboxy-3-[3-[(5E,8E,11E,14E,17E)-icosa-5,8,11,14,17-pentaenoyl]oxy-2-[(5E,8E,11E)-tetradeca-5,8,11-trienoyl]oxypropoxy]propyl]-trimethylazanium
[1-carboxy-3-[3-[(7E,9E,11E,13E,15E,17E)-icosa-7,9,11,13,15,17-hexaenoyl]oxy-2-[(7E,9E)-tetradeca-7,9-dienoyl]oxypropoxy]propyl]-trimethylazanium
[(2R)-2-[(E)-octadec-13-enoyl]oxy-3-phosphonooxypropyl] (8E,11E,14E)-icosa-8,11,14-trienoate
[(2R)-1-[(E)-octadec-7-enoyl]oxy-3-phosphonooxypropan-2-yl] (5E,8E,11E)-icosa-5,8,11-trienoate
[(2R)-2-[(6E,9E)-octadeca-6,9-dienoyl]oxy-3-phosphonooxypropyl] (11E,14E)-icosa-11,14-dienoate
[(2R)-2-[(E)-tetradec-9-enoyl]oxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropyl] (6E,9E)-octadeca-6,9-dienoate
[1-carboxy-3-[3-[(4E,7E,10E,13E,16E)-nonadeca-4,7,10,13,16-pentaenoyl]oxy-2-[(6E,9E,12E)-pentadeca-6,9,12-trienoyl]oxypropoxy]propyl]-trimethylazanium
[(2R)-1-[(6E,9E)-octadeca-6,9-dienoyl]oxy-3-phosphonooxypropan-2-yl] (11E,14E)-icosa-11,14-dienoate
[(2S)-1-[(E)-tetradec-9-enoyl]oxy-3-[(2R,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (6E,9E)-octadeca-6,9-dienoate
[(2R)-1-[(9E,12E)-octadeca-9,12-dienoyl]oxy-3-phosphonooxypropan-2-yl] (11E,14E)-icosa-11,14-dienoate
[(2R)-2-[(E)-pentadec-9-enoyl]oxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropyl] (9E,12E)-heptadeca-9,12-dienoate
[(2R)-1-phosphonooxy-3-tetradecanoyloxypropan-2-yl] (5E,8E,11E,14E)-tetracosa-5,8,11,14-tetraenoate
[(2R)-2-[(E)-octadec-4-enoyl]oxy-3-phosphonooxypropyl] (5E,8E,11E)-icosa-5,8,11-trienoate
[1-carboxy-3-[3-[(9E,11E,13E)-hexadeca-9,11,13-trienoyl]oxy-2-[(7E,9E,11E,13E,15E)-octadeca-7,9,11,13,15-pentaenoyl]oxypropoxy]propyl]-trimethylazanium
[(2R)-2-[(6E,9E)-octadeca-6,9-dienoyl]oxy-3-phosphonooxypropyl] (5E,8E)-icosa-5,8-dienoate
[1-carboxy-3-[3-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]oxy-2-[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoyl]oxypropoxy]propyl]-trimethylazanium
[1-carboxy-3-[3-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxy-2-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoyl]oxypropoxy]propyl]-trimethylazanium
2-[carboxy-[2-hydroxy-3-[(7Z,10Z,13Z,16Z,19Z,22Z,25Z,28Z,31Z)-tetratriaconta-7,10,13,16,19,22,25,28,31-nonaenoyl]oxypropoxy]methoxy]ethyl-trimethylazanium
1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphate
A 1-acyl-2-arachidonoyl-sn-glycero-3-phosphate in which the 1-acyl group is specified as stearoyl (octadecanoyl).
BisMePA(36:4)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
